Newsflash:
- Many Drug Labels Missing Dose, Safety Info for Kids
- Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer
- J&J Opens Doxil Rationing Program to New Patients
- FDA Issues Safety Label Changes for Fingolimod
- FDA Backs Pill to Block HIV Infection
- FDA Advisers Recommend Approving Arena Weight-Loss Drug
Study Finds No Drug-Drug Interaction Between Aggrenox 25mg/200mg Capsules and Omeprazole
Boehringer Ingelheim Pharmaceuticals Press Release (02/03/12)
Boehringer Ingelheim presented results of a drug interaction study that found Aggrenox (aspirin/extended-release dipyridamole), an antiplatelet medication, is not affected by the co-administration of omeprazole, a proton pump inhibitor (PPI), frequently used to treat several gastrointestinal conditions. The data were presented at the International Stroke Conference in New Orleans.
Abstract News © Copyright 2011
INFORMATION, INC.
Sponsor Highlights
Our Sponsors:
Sitemap
© Pharmacist e-Link
